A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years (QALYs) at a significantly high cost, according to an analysis published in Cancer...
A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years (QALYs) at a significantly high cost, according to an analysis published in Cancer...
A...